Author:
Xi Yanfeng,Xu Chen,Liu Yiqiang,Yan Xiaochu,Huang Chuansheng,Liu Yueping,Mei Jinhong,Wang Zhe,Liu Bin,Li Xiaoming,Li Wencai,Lan Jianyun,Gao Peng,Wu Jifeng,Zheng Jianming,Hou Yingyong
Funder
Shanghai Municipal Key Clinical Specialty
Shanghai Science and Technology Development Fund
Subject
Cell Biology,Pathology and Forensic Medicine
Reference31 articles.
1. Ideal number of biopsy tumor fragments for predicting HER2 status in gastric carcinoma resection specimens;Ahn;Oncotarget,2015
2. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial;Bang;Lancet,2010
3. HER2 testing and clinical decision making in gastroesophageal adenocarcinoma: guideline from the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology;Bartley;Arch. Pathol. Lab. Med.,2016
4. WHO Classification of Tumours of the Digestive System;Bosman,2010
5. Cancer statistics in China, 2015;Chen;CA Cancer J. Clin.,2016